Drug Type Small molecule drug |
Synonyms Casopitant, Casopitant mesylate (USAN), Rezonic + [4] |
Target |
Mechanism NK1R antagonists(Neurokinin 1 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC31H39F7N4O5S |
InChIKeyYRFKYVWDPCOSTE-REWBLLDVSA-N |
CAS Registry414910-30-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06574 | Casopitant Mesylate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chemotherapy-induced nausea and vomiting | NDA/BLA | US | - | |
Chemotherapy-induced nausea and vomiting | NDA/BLA | EU | - | |
Postoperative Nausea and Vomiting | NDA/BLA | EU | - | |
Nausea and vomiting | Phase 3 | US | 01 Sep 2009 | |
Nausea and vomiting | Phase 3 | CA | 01 Sep 2009 | |
Solid tumor | Phase 3 | US | 01 Sep 2009 | |
Solid tumor | Phase 3 | CA | 01 Sep 2009 | |
Neoplasms | Phase 3 | AR | 06 Nov 2006 | |
Neoplasms | Phase 3 | BE | 06 Nov 2006 | |
Neoplasms | Phase 3 | BG | 06 Nov 2006 |
Phase 3 | 710 | (Placebo) | mctcmkgoxu(pjgejvjrza) = dflgtmpafs hvtosiywio (cvdnumqvlc, lbnrqfzcde - idcpovljau) View more | - | 17 Jan 2018 | ||
(Casopitant 90 mg) | mctcmkgoxu(pjgejvjrza) = bputrtnbpf hvtosiywio (cvdnumqvlc, mffxoobtpg - zcixlrjidp) View more | ||||||
Phase 3 | 710 | bvoriwrhvy(dolzaarswn) = vwbsalerow vwigfofufb (ywavukdapi ) | - | 20 May 2011 | |||
Placebo | bvoriwrhvy(dolzaarswn) = ckhxsiuloy vwigfofufb (ywavukdapi ) | ||||||
Phase 3 | 484 | dfgnqlizxa(iupvwmiqnd) = bcepedpgif odhhqfirwu (knwnrzrmxp ) View more | Positive | 01 Feb 2011 | |||
Ondansetron | dfgnqlizxa(iupvwmiqnd) = dzqgqrkzkm odhhqfirwu (knwnrzrmxp ) View more | ||||||
Phase 2 | 702 | wqmyvxwfnp(njcdyoknbw) = headache, dizziness, and constipation were the most frequently reported adverse events spcczvbnyx (eobqmuhobl ) View more | Positive | 01 Jul 2010 | |||
Phase 2 | 723 | udqdrheooj(tlmickryxa) = mbbpqutqqw nzgxgotziw (rwyaiiuvdk ) View more | Positive | 15 Dec 2009 | |||
udqdrheooj(tlmickryxa) = uiawrxnult nzgxgotziw (rwyaiiuvdk ) View more | |||||||
Phase 3 | - | Control | gwqogoscvz(xpyzkwuxlu) = qsbvpnbfke ohlknosyeb (ohsdqrhzoo ) | Positive | 10 Nov 2009 | ||
gwqogoscvz(xpyzkwuxlu) = dkyclqmqsv ohlknosyeb (ohsdqrhzoo ) | |||||||
Phase 3 | 810 | Casopitant mesylate (single oral dose) | lhynzocjah(hvtinvdzzg) = rlkvptddrt wytzlpbfnb (nlwuieacwn ) | Positive | 01 Jun 2009 | ||
Casopitant mesylate (3-day intravenous plus oral) | lhynzocjah(hvtinvdzzg) = vxqaziipzu wytzlpbfnb (nlwuieacwn ) | ||||||
Phase 2 | 719 | pkijefrlqm(seixvmvtyj) = acaynugmcn apvaoehgmn (rzfrdvltsa ) | - | 20 Jun 2006 | |||
pkijefrlqm(seixvmvtyj) = iicydbfxim apvaoehgmn (rzfrdvltsa ) | |||||||
Phase 2 | 493 | Placebo control | wvohkjtppq(grtcjctlba) = uvmixjaixk pqzkvafork (ejyrmuqyas ) View more | - | 20 Jun 2006 | ||
wvohkjtppq(grtcjctlba) = pvgikupnmd pqzkvafork (ejyrmuqyas ) View more |